5,6-Diphenyl-2-mercapto-pyrazin | 17705-32-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5,6-Diphenyl-2-mercapto-pyrazin
• 英文别名: 5,6-Diphenyl-2-pyrazinethiol；5,6-diphenyl-1H-pyrazine-2-thione
• CAS: 17705-32-7
• 化学式: C₁₆H₁₂N₂S
• 分子量: 264.351
• InChiKey: TUCXPBLFXXNRBH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  19
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  56.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5,6-Diphenyl-2-mercapto-pyrazin 在 马来酸酐 、 双氧水 、 sodium carbonate 作用下， 以 氯仿 、 丙酮 为溶剂， 反应 7.0h， 生成 5,6-diphenyl-2-cyanomethylsulfinylpyrazine
  参考文献：
  名称：

  b-Elimination of the Pyrazinylsulfinyl Group — Preparation of Cinnamonitriles

  摘要：

  DOI：

  10.3987/com-87-4379
• 作为产物：
  描述：

  5，6-二苯基-2-羟基吡嗪 在 劳森试剂 作用下， 以 苯 为溶剂， 反应 3.5h， 以97%的产率得到5,6-Diphenyl-2-mercapto-pyrazin
  参考文献：
  名称：

  b-Elimination of the Pyrazinylsulfinyl Group — Preparation of Cinnamonitriles

  摘要：

  DOI：

  10.3987/com-87-4379

文献信息

• Selexipag: An Oral and Selective IP Prostacyclin Receptor Agonist for the Treatment of Pulmonary Arterial Hypertension
  作者：Tetsuo Asaki、Keiichi Kuwano、Keith Morrison、John Gatfield、Taisuke Hamamoto、Martine Clozel

  DOI：10.1021/acs.jmedchem.5b00698

  日期：2015.9.24

  Prostacyclin controls cardiovascular function via activation of the prostacyclin receptor. Decreased prostacyclin production occurs in several cardiovascular diseases. However, the clinical use of prostacyclin and its analogues is complicated by their chemical and metabolic instability. A medicinal chemistry program searched for novel nonprostanoid prostacyclin receptor agonists not subject to these

  前列环素通过前列环素受体的激活来控制心血管功能。前列环素产生的减少发生在几种心血管疾病中。然而，前列环素及其类似物的临床使用由于其化学和代谢不稳定而变得复杂。一项药物化学程序正在寻找不受这些限制的新型非前列腺素类前列环素受体激动剂。合成具有二苯基吡嗪结构核心的化合物。通过修饰线性侧链优化了代谢稳定性和激动剂效能。化合物12b（MRE-269，ACT-333679）被鉴定为有效且高度选择性的前列环素受体激动剂。用N取代末端羧基-酰基磺酰胺基产生母体化合物26a（selexipag，NS-304，ACT-293987），该化合物具有口服活性，并提供持续的12b血浆暴露。化合物26a被开发用于治疗肺动脉高压，并在3期事件驱动的临床试验中显示出降低复合发病率/死亡率终点的风险。
• Thiols in Ugi- and Passerini-Smiles-Type Couplings
  作者：Anaëlle Barthelon、Laurent El Kaïm、Marie Gizolme、Laurence Grimaud

  DOI：10.1002/ejoc.200800859

  日期：2008.12

  The use of the Smiles rearrangement in Ugi-type couplings with aromatic mercaptans allows for the straightforward, multicomponent formation of α-arylamino thiocarboxamides. The scope of this new four-component coupling is further broadened with the use of heterocyclic mercapto derivatives that afford thioamides of high biological interest in one step. (© Wiley-VCH Verlag GmbH & Co. KGaA, 69451 Weinheim

  在具有芳香族硫醇的Ugi型偶联中使用Smiles重排可以直接，多组分地形成α-芳基氨基硫代羧酰胺。通过使用杂环巯基衍生物可进一步扩大这种新的四组分偶联的范围，该杂环巯基衍生物可在一步之内提供具有高度生物学意义的硫代酰胺。（©Wiley-VCH Verlag GmbH＆Co.KGaA，69451 Weinheim，Germany，2008）
• Heterocyclic compound derivatives and medicines
  申请人：——

  公开号：US20040102436A1

  公开（公告）日：2004-05-27

  The present invention provides a compound which is useful as a PGI 2 receptor agonist, and a pharmaceutical composition. The present invention is directed to a pharmaceutical composition comprising a compound represented by the following formula [1]: 1 (R 1 and R 2 are the same or different and each represents optionally substituted aryl, Y represents N or CH, Z represents N or CH, A represents NH, NR 5 , O, S, or ethylene, R 5 represents alkyl, D represents alkylene or alkenylene, E represents phenylene or single bond, G represents O, S, or CH 2 , R 3 and R 4 are the same or different and each represents hydrogen or alkyl, Q represents carboxy, alkoxycarbonyl, tetrazolyl, carbamoyl, or N-(alkylsulfonyl)carbamoyl), or a pharmaceutically acceptable salt thereof as an active ingredient.

  本发明提供了一种作为PGI2受体激动剂有用的化合物和制药组合物。本发明涉及一种制药组合物，其包括由以下式子[1]表示的化合物：1（其中R1和R2相同或不同，每个表示可选择取代的芳基，Y表示N或CH，Z表示N或CH，A表示NH、NR5、O、S或乙烯，R5表示烷基，D表示烷基或烯基，E表示苯基或单键，G表示O、S或CH2，R3和R4相同或不同，每个表示氢或烷基，Q表示羧基、烷氧羰基、四唑基、氨基甲酰基或N-(烷基磺酰)氨基甲酰基），或其药学上可接受的盐作为活性成分。
• HETEROCYCLIC COMPOUND DERIVATIVES AND MEDICINES
  申请人：Nippon Shinyaku Co., Ltd.

  公开号：EP1400518B1

  公开（公告）日：2007-01-17
• Structure–activity studies on diphenylpyrazine derivatives: A novel class of prostacyclin receptor agonists
  作者：Tetsuo Asaki、Taisuke Hamamoto、Yukiteru Sugiyama、Keiichi Kuwano、Kenji Kuwabara

  DOI：10.1016/j.bmc.2007.08.010

  日期：2007.11

  To develop nonprostanoid prostacyclin receptor agonists with a high degree of metabolic resistance and an extended duration of action, a novel series of diphenylpyrazine derivatives was synthesized and evaluated for their inhibition of ADP-induced human platelet aggregation. Structure-activity relationship studies on the side chain containing the carboxylic acid moiety of the lead compound 5c showed that the length of the linker and the presence of the concatenating nitrogen atom adjacent to the pyrazine ring are critical for the antiaggregatory activity. This study led to the discovery of 2-amino-5,6-diphenylpyrazine derivatives 8c, 15a, and 15b. which showed potent inhibition of platelet aggregation with IC50 values of 0.2 mu M. Among these compounds, 15b is an orally available and long-lasting prostacyclin receptor agonist which is promising for the treatment of various vascular diseases. (C) 2007 Elsevier Ltd. All rights reserved.